Moderate levels of alcohol consumption linked to higher risk of some cancers, NCI writes in JAMA

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Even moderate levels of alcohol consumption appear to be associated with a higher risk of some cancers—including cancers of the female breast—as well as adverse cardiovascular health effects, NCI researchers wrote in JAMA.

The article, “Alcohol and Cancer: Research and Clinical Implications,” is co-authored by three associate directors in the Division of Cancer Control and Population Sciences at NCI.

The paper highlights the low awareness of the association between alcohol use and cancer and makes a call for increasing clinician knowledge and patient-provider communication regarding the effects of alcohol on cancer. The authors also supports increased focus and research on the harms of moderate drinking, in addition to the more commonly studied harms from risky drinking and alcohol use disorders.

Alcohol is associated with almost 90,000 cases of cancer of the oral cavity, throat, liver, female breast, and colorectum per year. Awareness of this relationship is low not only in the U.S., but worldwide. The paper also notes evidence that reductions in alcohol use are associated with decreased cancer mortality.

Table of Contents

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login